Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-PeriOp GC platform study in resectable locally advanced gastroesophageal adenocarcinoma
CTR20252412Phase 2Suspended
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sonesitatug vedotin, rilvegostomig, trastuzumab deruxtecan in gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Jul 2025; status: suspended.
02
Drugs
sonesitatug vedotinrilvegostomigtrastuzumab deruxtecan
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252412.